The "Squawk on the Street" news team reports on today's top business headlines, including reaction to April's jobs data; Warren Buffett's take on the economy; and the outlook on LinkedIn.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Some of the names on the move ahead of the open.
Warren Buffett shares his views on the Fed's bond buying policy, with CNBC's Becky Quick.
Mario Gabelli, Gabelli Funds; and Douglas Kass, Seabreeze Partners Management, debate the state of Berkshire's business.
Jeffrey Saut, Raymond James strategist, shares where he is putting money to work as the S&P 500 hits another record high.
CNBC's Becky Quick; and John Rogers, Ariel Investments chairman & CEO, discuss why he believes the markets are headed higher.
CNBC's Geoff Cutmore reports why the ECB's Ewald Nowotny moved the euro.
CBS reported a strong first quarter this week, and traders apparently think that the good news will keep on coming.
CNBC's Kelly Evans reports on Friday's market moving events from Europe, as investors await the release of nonfarm payrolls data in the U.S.
There’s been a relentless rally in these stocks, Cramer said. And it’s probably not over.
Mad Money host Jim Cramer shares his final thoughts of the day.
Charles River Laboratories CEO James Foster discusses the company's recent quarter, the impact from the sequester, and the role his company plays in helping large and small companies move their drugs into the pipeline.
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
Mike Mayo, Bank Analyst at CLSA says revenue growth at U.S banks is weak, but believes there are a still few stocks that are worth your money.
After the huge spill back in 2010, Cramer examines which Gulf plays may be worth owning today.
The Gulf of Mexico is having an oil and gas production renaissance right now, explains Mad Money host Jim Cramer. How to play BP, Chevron and ConocoPhillips now.
In a market moving interview with the CEO of Allergan, Cramer was first to learn that the FDA had voted in favor of the company's new volumizing filler called Voluma.
Allergan reported positive earnings on Wednesday, but the stock tumbled after. Its CEO David Pyott discusses earnings, drug delays and the future of the company.
Jim Cramer believes a major catalyst is changing in the market. The implications are big.